Terms: = Gastric cancer AND CEP17
26 results:
1. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract] [Full Text] [Related]
2. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced gastric cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and gastric cancers.
Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
[TBL] [Abstract] [Full Text] [Related]
4. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
[TBL] [Abstract] [Full Text] [Related]
5. Three Trocars Laparoscopic Total Gastrectomy + D2 Lymphadenectomy with Intracorporeal Manual Esojejunostomy.
Dapri G; Gomez MG; Cadière GB; Yang HK
Ann Surg Oncol; 2017 Jun; 24(6):1658-1659. PubMed ID: 28120132
[TBL] [Abstract] [Full Text] [Related]
6. Tumor Content Chart-Assisted HER2/cep17 Digital PCR Analysis of gastric cancer Biopsy Specimens.
Matsusaka K; Ishikawa S; Nakayama A; Ushiku T; Nishimoto A; Urabe M; Kaneko N; Kunita A; Kaneda A; Aburatani H; Fujishiro M; Seto Y; Fukayama M
PLoS One; 2016; 11(4):e0154430. PubMed ID: 27119558
[TBL] [Abstract] [Full Text] [Related]
7. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract] [Full Text] [Related]
8. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract] [Full Text] [Related]
9. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
Catenacci DVT; Liao WL; Zhao L; Whitcomb E; Henderson L; O'Day E; Xu P; Thyparambil S; Krizman D; Bengali K; Uzzell J; Darfler M; Cecchi F; Blackler A; Bang YJ; Hart J; Xiao SY; Lee SM; Burrows J; Hembrough T
Gastric Cancer; 2016 Oct; 19(4):1066-1079. PubMed ID: 26581548
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of HER2 by automated FISH and IHC in gastric carcinoma biopsies.
Silva MR; Alarcão A; Ferreira T; d'Aguiar M; Ladeirinha A; Balseiro S; Carvalho L
Int J Biol Markers; 2016 Feb; 31(1):e38-43. PubMed ID: 26349667
[TBL] [Abstract] [Full Text] [Related]
11. HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal gastric cancer Cases.
Liu X; Wang X; Wang B; Ren G; Ding W
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):459-64. PubMed ID: 26317310
[TBL] [Abstract] [Full Text] [Related]
12. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications.
Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2016 Apr; 19(2):421-430. PubMed ID: 26002144
[TBL] [Abstract] [Full Text] [Related]
13. Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced gastric cancer.
Ock CY; Lee KW; Kim JW; Kim JS; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Kim WH; Bang YJ; Oh DY
Clin Cancer Res; 2015 Jun; 21(11):2520-9. PubMed ID: 25712681
[TBL] [Abstract] [Full Text] [Related]
14. HER2 Genetic Heterogeneity in gastric cancer: Evaluation According to the College of American Pathologists Breast cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract] [Full Text] [Related]
15. Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.
Chao WR; Lee MY; Lin WL; Koo CL; Sheu GT; Han CP
Am J Surg Pathol; 2014 Sep; 38(9):1227-34. PubMed ID: 25133707
[TBL] [Abstract] [Full Text] [Related]
16. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
[TBL] [Abstract] [Full Text] [Related]
17. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: cep17 ratio?
Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
[TBL] [Abstract] [Full Text] [Related]
18. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
[TBL] [Abstract] [Full Text] [Related]
19. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
Grin A; Brezden-Masley C; Bauer S; Streutker CJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
[TBL] [Abstract] [Full Text] [Related]
20. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
[TBL] [Abstract] [Full Text] [Related]
[Next]
